Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Justin Balko on the Diversity of Genetic Alterations in TNBC

December 8th 2012

Justin M. Balko, PharmD, PhD, from the Vanderbilt-Ingram Cancer Center, discusses research into clinically targetable genetic alterations in patients with triple-negative breast cancer.

Long-Term Follow-Up Supports Use of Hypofractionated Radiotherapy in Early-Stage Breast Cancer

December 7th 2012

Long-term follow-up results showed that the hypofractionated regimens were as effective as the 50-Gy standard in women with early-stage breast cancer.

Long-Term Data Confirms One-Year of Adjuvant Trastuzumab as Standard of Care

December 7th 2012

Eight-year follow-up data from the phase III HERA trial has confirmed that 1-year of adjuvant trastuzumab should remain the treatment standard in women with HER2-positive early-stage breast cancer.

Dr. Yarnold on Hypofractionation in the START Trials

December 7th 2012

John Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.

Adjuvant Bevacizumab Falls Short in Triple-Negative Breast Cancer

December 7th 2012

Patients with triple-negative breast cancer had no statistically significant improvement in disease-free survival when they received adjuvant treatment with chemotherapy plus 1 year of bevacizumab.

Dr. Leyland-Jones Discusses the Phase III HERA Trial

December 7th 2012

Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.

Study Shows Eribulin Not Superior to Capecitabine in Previously Treated Metastatic Breast Cancer

December 7th 2012

Eribulin mesylate failed to show a statistically significant survival benefit compared with capecitabine in women with previously treated metastatic breast cancer.

Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer

December 6th 2012

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

Dr. Bhalla on Sensitizing TNBC to PARP Inhibitors and Cisplatin

December 6th 2012

Kapil N. Bhalla, MD, from the University of Kansas Cancer Center, describes an in vivo study that examined treatment with histone deacetylase inhibitors in triple-negative breast cancer cells.

Dr. Aebi on Adjuvant Chemo in Recurrent Breast Cancer

December 6th 2012

Stefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.

HDAC Inhibition Appears to Sensitize Triple-Negative Breast Cancer Cells to Certain Treatments

December 6th 2012

Preliminary research suggests that in-vitro exposure to an HDAC inhibitor may sensitize triple-negative breast cancer cells to treatment with a PARP inhibitor and cisplatin.

Adjuvant Chemotherapy Improves Survival in Women With Recurrent Breast Cancer

December 6th 2012

Adjuvant chemotherapy improved survival rates in women with isolated local or regional breast cancer recurrence, according to results from the CALOR trial.

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

December 5th 2012

Postmenopausal women with advanced estrogen receptorâ€“positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

December 5th 2012

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Sentinel Lymph Node Surgery After Chemotherapy Shows Accuracy in Nodal Staging in Breast Cancer

December 5th 2012

Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.

Adjuvant Tamoxifen for 10 Years Better Than 5 Years in ER-Positive Breast Cancer

December 5th 2012

Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.

Dr. Boughey on Reducing False Negatives in SLN Surgery

December 5th 2012

Judy C. Boughey, MD, from the Mayo Clinic in Rochester, MN, discusses surgical techniques examined in the Z1071 study that could help minimize the false negative rates experienced with SLN surgery.

Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

December 5th 2012

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

5 Subtyping Questions for Matthew J.C. Ellis, MB BChir, PhD

December 4th 2012

For the past 10 years, Matthew J.C. Ellis, MB BChir, PhD, has focused his research on exploring the breast cancer genome in partnerships with academic and government-funded centers in the United States and the United Kingdom.

Subtyping Breast Cancer: Genome Analysis Opens Door to New Era in Targeted Therapies

December 4th 2012

The clinical subtyping of breast cancer appears to be coming into a golden era as an increased understanding of subtyping promises to help advance treatments and outcomes for patients.